Clinical trials: Hepatic Function Abnormal
HIV Infection, Hepatitis C
An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C
The purpose of this study is to confirm the safety, efficacy and delineate the pharmacokinetic properties of nelfinavir in HIV/ Hepatitis C coinfected subjects with Child Pugh A compensated cirrhosis and or Hepatic fibrosis
- Trial name
- NCT00141284
- Testing
- nelfinavir 1,250 mg twice daily, Zidovudine 300 mg twice daily, Lamivudine 150 mg twice daily
- Where
- 5 sites in United States, Canada
- Volunteers
- 12 people
- Sponsor
- Pfizer
Oncology
Pharmacokinetics of Entospletinib in Adults With Normal and Impaired Liver Function
The primary objective of this study is to evaluate the pharmacokinetics of entospletinib (ENTO) and/or its metabolites (if applicable) in participants with impaired hepatic function (stratified by smoking status, as appropriate)…
- Trial name
- NCT02521376
- Testing
- Entospletinib
- Where
- 6 sites in United States, Germany and 1 more
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Gilead Sciences
Hepatitis b & Liver Dysfunction
Study on PK of Hydronidone in Patients and Special Population
1. Evaluate the pharmacokinetic (PK) characteristics of Hydronidone capsule in target patients (patients with chronic viral hepatitis b with liver fibrosis) and special population (patients with mild liver dysfunction). 2.
- Trial name
- NCT04123769
- Testing
- Hydronidone
- Where
- China
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Beijing Continent Pharmaceutical Co, Ltd.
Hepatic Insufficiency, Cirrhosis, Liver
Diagnosis of Lymphohistiocytic Hemophagocytosis in Intensive Care
Patients with hepatocellular insufficiency and/or cirrhosis are at risk of developing invasive fungal infections, particularly in critical care settings.
- Trial name
- SAMICU (NCT07343037)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
Liver Dysfunction
FC Change From Day 1 to Day 3 Associated With SALD
As defined by sepsis 3.0, sepsis is a clinical syndrome caused by disordered host response to serious infection，leading to multiple organ dysfunction1.
- Trial name
- 2024-04-22 (NCT06403553)
- Testing
- Fecal Calprotectin
- Where
- China
- Volunteers
- 96 people
- Sponsor
- Chinese Medical Association
Malignant Melanoma
Pharmacokinetic Study of Liposomal Vincristine in Patients With Malignant Melanoma & Hepatic Dysfunction
The purpose of this study is to see how vincristine, when placed in an oil droplet called a liposome (VSLI), is absorbed, distributed (moved around) and excreted from the the body (pharmacokinetics).
- Trial name
- NCT00145041
- Testing
- Vincristine Sulfate Liposomes Injection
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Acrotech Biopharma Inc.
Renal Insufficiency, Hepatic Insufficiency
Study to Evaluate the Effects of Underlying Renal or Hepatic Dysfunction on the Pharmacokinetics of Nevirapine
Study to assess the effects of varying degrees of renal dysfunction and hepatic insufficiency on the single-dose pharmacokinetics of nevirapine and nevirapine metabolites in order to establish an appropriate dose and/or dosing…
- Trial name
- NCT02184091
- Testing
- Nevirapine
- Volunteers
- 41 people
- Sponsor
- Boehringer Ingelheim
Solid Tumor, Adult, Impaired Liver Function
Oral Docetaxel in Patients With Normal or Impaired Liver Function
This is an open label, single centre pharmacological and safety study to define the safety and pharmacokinetics of ModraDoc006/r in a weekly dosing schedule in patients with impaired liver function who might have benefit from a…
- Trial name
- NCT05084456
- Testing
- ModraDoc006/r
- Where
- Netherlands
- Sponsor
- Modra Pharmaceuticals
Advanced Cancer, Hepatic Impairment
Phase 1 PK Study of Cediranib in Single and Multiple Doses in Hepatically Impaired Patients With Solid Tumours
To determine how patients with advanced cancer and various degrees of hepatic impairment will metabolise Cediranib.
- Trial name
- NCT00621725
- Testing
- AZD2171
- Where
- 3 sites in Denmark, Netherlands
- Volunteers
- 36 people
- Sponsor
- AstraZeneca
Hematopoietic Stem Cell Transplant
Prevalence and Development of Liver Dysfunction in Hematopoietic Stem Cell Transplant
Background: Hematopoietic stem cell transplant (HSCT) is a common treatment for many cancers and other illnesses. But many people who have HSCT go on to develop liver dysfunction.
- Trial name
- NCT05722210
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Unspecified Adult Solid Tumor, Protocol Specific
Oxaliplatin in Treating Patients With Advanced Cancer Plus Liver Dysfunction
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of oxaliplatin in treating patients who have advanced…
- Trial name
- NCT00005077
- Testing
- oxaliplatin
- Where
- 11 sites in United States
- Sponsor
- City of Hope Medical Center
Liver Dysfunction, Circulatory; Change
Study of Hemodynamic Conditions Measured During Hepatectomy
Hepatocellular insufficiency is a dreaded complication after hepatectomy, since, if it is persistent, it leads to the death of the patient in the absence of liver transplantation.
- Trial name
- DEBIFOIE (NCT03371537)
- Testing
- Liver debit measure
- Where
- France
- Volunteers
- 9 people
- Sponsor
- University Hospital, Tours
Liver Cirrhosis, Kidney Failure, Acute
Intermittent ADVOS vs. Hemodialysis in Non-intensive Care Patients With Liver Dysfunction
In the planned randomized controlled prospective pilot study, we aim to evaluate ADVOS compared with conventional hemodialysis regarding the elimination of protein-bound toxins in patients with therapy-refractory hepatorenal…
- Conditions
- Liver Cirrhosis, Kidney Failure, Acute, Kidney Replacement, Multi Organ Failure
- Trial name
- ADVOMITTENT (NCT06129617)
- Testing
- Hemodialysis, ADVOS
- Where
- Germany
- Volunteers
- 14 people
- Sponsor
- University Medical Center Mainz
Hepatic Insufficiency
Safety and Pharmacokinetics of Indacaterol in Healthy Subjects and Those With Impaired Liver Function
This study is designed to evaluate the safety and pharmacokinetic effects of indacaterol in subjects with impaired liver function in comparison with healthy subjects
- Trial name
- NCT00416702
- Testing
- QAB149
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Novartis
Gut Microbiota, Intra-abdominal Infections
Gut Microbiota Analysis in IAI Patients With Sepsis-associated Liver Dysfunction
With the rapid development of intensive care medicine, the mortality of patients with sepsis has decreased over the past decade, but it is still the leading cause of death in intensive care unit (ICU).
- Conditions
- Gut Microbiota, Intra-abdominal Infections, Acute Gastrointestinal Injury, Sepsis-associated Liver Dysfunction
- Trial name
- 2022-11-09 (NCT05628493)
- Testing
- Gut microbiota Analysis
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese Medical Association
Non-small Cell Lung Cancer
Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy
To assess the efficacy and safety of Almonertinib therapy in patients with abnormal liver function after first/second generation EGFR-TKI treatment, or Almonertinib first-line therapy in patients with basic hepatopathy and…
- Trial name
- NCT05662813
- Testing
- Almonertinib
- Where
- China
- Volunteers
- 55 people
- Sponsor
- West China Hospital
Abnormal Liver Function
Comparison of 19g FNA and 19g FNB Needles for EUS-LB
Chronic liver disorders (CLD) are a major cause of morbidity and mortality for individuals in the US. Though serologic analysis will often lead to a conclusive diagnosis, liver biopsy remains an important method for helping to…
- Trial name
- NCT03408171
- Testing
- 19-gauge FNA needle, 19-gauge FNB needle
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Geisinger Clinic
Hepatic Impairment, Healthy Subjects
Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Liver Function
This study is designed to evaluate the safety and pharmacokinetics of Fluzoparib in subjects with impaired liver function in comparison with healthy subjects ,to develop dose recommendations for patients with hepatic impairment.
- Trial name
- NCT04694365
- Testing
- Fluzoparib
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Liver Diseases, Hepatic Insufficiency
A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease
The main purpose of this study is to measure how much of the study drug called baricitinib gets into the blood stream and how long it takes the body to get rid of it. Healthy participants and those with liver disease may enroll.
- Trial name
- NCT01870388
- Testing
- Baricitinib
- Where
- 2 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Hepatic Complications, Malignant Neoplasm
Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction
Bortezomib may stop the growth of cancer cells by blocking the enzymes necessary for their growth. This phase I trial is studying the side effects and best dose of bortezomib in treating patients with advanced cancer and liver…
- Trial name
- NCT00091117
- Testing
- bortezomib, pharmacological study
- Where
- 3 sites in United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)